Phase I/IIa Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies

Trial Profile

Phase I/IIa Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Cerulean Pharma; NewLink Genetics Corporation
  • Most Recent Events

    • 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
    • 06 Oct 2016 According to a Cerulean Pharma media release, data from the study will be presented at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top